ACE inhibitors and the kidney. A risk-benefit assessment

Drug Safety

Volumn 15, Issue 3, 1996, Pages 200-211

  Navis, Gerjan ^a   Faber, Harald J ^a   De Zeeuw, Dick ^a   De Jong, Paul E ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM ION; SODIUM ION;

ACUTE KIDNEY FAILURE; ANTIHYPERTENSIVE ACTIVITY; BLOOD VESSEL TONE; CHRONIC KIDNEY DISEASE; DRUG MONITORING; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEMODYNAMICS; HUMAN; HYPERTENSION; KIDNEY; KIDNEY FUNCTION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK BENEFIT ANALYSIS; SODIUM DEPLETION; SODIUM RESTRICTION; SYSTEMIC VASCULAR RESISTANCE; VASODILATATION;

EID: 0029833636     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199615030-00005     Document Type: Review

References (110)

1. Heerdink ER, Leufkens HG, Glerum JH, et al. Polypharmacy in the elderly: clustering of drug use. In: Clustering of drug use in the elderly [thesis]. University of Utrecht: 1995; 65-80
2. Captopril: benefits and risks in severe hypertension [editortal]. Lancet 1980; II: 129-30.
3. Parving H-H, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by eaptopril in insulin-dependent diabetics with nephropathy. BMJ 1988; 297: 1086-91
4. Heeg JE, de Jong PE, van der Hem, et al. Reduction of proteinuria by angiotensin convening enzyme inhibition. Kidney Int 1987; 32: 78-83
5. Raij L, Keane WF. Glomerular mesangium: its function and relationship to angiotensin II. Am J Med 1985; 79 Suppl. 3c: 24-30
6. Schor N, Ichikawa I, Brenner BM. Mechanism of action of various hormones and vasoactive substances on glomerular ultrafiltration in the rat. Kidney Int 1981; 20: 442-51
7. Hricik DE. Captopril-induced renal insufficiency and the role of sodium balance. Ann Intern Med 1985; 103: 222-3
8. Schuster V. Effect of angiotensin on proximal tubular reabsorption. Fed Proc 1986; 45: 1444-7
9. Hollenberg NK, Swartz SL, Passan DR. Increased glomerular filtration rate after converting enzyme inhibition in essential hypertension. N Engl J Med 1979; 29: 9-12
10. Atlas SA, Case DB, Sealey JE, et al. Interruption of the reninangiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension 1979; 1: 274-80
11. Tarazi RC, Bravo EL, Fouad FM, et al. Hemodynamic and volume changes associated with captopril. Hypertension 1980; 2: 576-85
12. Berk BC, Vekshtein V, Gordon HM, et al. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 1989; 13: 305-14
13. Wolthuis A, Boes A, Rodemann HP, et al. Vasoactive agents affect growth and protein synthesis of cultured mesangial cells. Kidney Int 1992; 41: 124-31
14. Kagami S, Border WA, Miller DE, et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-7
15. Grond J, Elema JD. Glomerular mesangium: analysis of the increased activity observed in experimental acute aminonucleoside nephrosis in the rat. Lab Invest 1981; 45; 400-9
16. Anderson SA, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibition in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993-2000
17. Wapstra FH, van Goor H, Navis GJ, et al. The antiproteinuric effect predicts renal protection by ACE-inhibition in rats with established adriamycin nephrosis. Clin Sci 1996; 90: 393-401
18. Johnston CI, Burrell LM. Evolution of blockade of the renin angiotensin system. J Hum Hypertens 1995; 9: 375-80
19. Navis GJ, de Jong PE, Donker AJM, et al. Diuretic effects of ACE-inhibition: comparison of low and liberal sodium diet in hypertensive patients. J Cardiovasc Pharmacol 1987; 9: 743-8
20. Heeg JE, de Jong PE, van der Hem GK, et al. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36: 272-9
21. Hollenberg NK, Meggs LG, Williams GH, et al. Sodium intake and renal responses to captopril in normal man and in essential hypertension. Kidney Int 1981; 20: 240-5
22. Navis GJ, de Jong PE, Donker AJM, et al. Moderate sodium restriction in hypertensive subjects: renal effects of ACE-inhibition. Kidney Int 1987; 31: 815-9
23. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low dose captopril for the treatment of mild to moderate hypertension. Arch Intern Med 1984; 144: 1947-53
24. Ruilope LM, Lahera V, Alcazar JM, et al. Randomly allocated study of the effects of standard therapy versus ACE inhibition on micro-albuminuria in essential hypertension. J Hypertens 1994; 12 (4) Suppl.: 59S-63S
25. Madhaven S, Stockwell D, Cohen H, et al. Renal function during antihypertensive treatment. Lancet 1995; 345: 749-51
26. Himmelmann A, Hansson L, Hanson B-G, et al. ACE-inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension. Blood Press 1995; 4: 85-90
27. Himmelmann A, Hansson L, Hansson B-G, et al. Superior renal preservation with an ACE-inhibitor in essential hypertension: a transient effect? [abstract] Proceedings of the 7th European Meeting on Hypertension; 1995 June 9-12; Milan, 81
28. Bravo EL, Tarazi RC. Efficacy of an orally active converting enzyme inhibitor (SQ 14,225) in the treatment of renovascular hypertension (RVH) in man. Kidney Int 1977; 12: 497-50
29. Derkx FHM, Tan-Tjiong HL, Wenting GJ. Captopril test for diagnosis of renovascular hypertension. In: Glorioso N, Laragh JH, Rapelli A, editors. Renovascular hypertension. New York: Raven Press, 1986: 70-5
30. Wenting GJ, Derkx FH, Tan-Tjiong LH, et al. Risks of angiotensin converting enzyme inhibition in renal artery stenosis. Kidney Int 1987; 31 Suppl. 20: 180S-183S
31. Textor SC, Tarazi RC, Novick AC, et al. Regulation of renal hemodynamies and glomerular filtration in patients with renovascular hypertension during converting enzyme inhibition with captopril. Am J Med 1984; 76: 29-37
32. Ribstein J, Mourad G, Mimran A. Contrasting acute effects of captopril and nifedipine on renal function in renovascular hypertension. Am J Hypertens 1988; 1: 239-44
33. Silas JH, Klenka A, Solomon SA. Captopril-induced reversible renal failure: a marker of renal artery stenosis affecting a solitary kidney. BMJ 1983; 286: 1702-3
34. van der Woude FJ, van Son W, Tegzess AM, et al. Effect of captopril on blood pressure and renal function in patients with transplant renal artery stenosis. Nephron 1985; 39: 184-8
35. Hricik DE, Browning PJ, Kopelman R, et al. Captopril-induced functional renal insufficiency in patients with bilateral renalartery stenosis or renal artery stenosis in a single kidney. N Engl J Med 1983; 308: 373-6
36. Durand D, Van Tran T, Ader JL. L'insufficance rénale apres administration de captopril dans les sténoses de l'artère rénale sur rein unique ou les sténoses bilatérales n'est pas obligatoire. Arch Mal Coeur 1984; 11: 1272-7
37. Salahudeen AK, Pingle A. Reversibility of captopril-induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension. J Hum Hypertens 1988; 2: 57
38. Hoefnagels WHL, Thien T. Renal artery occlusion in patients with renovascular hypertension treated with captopril. BMJ 1986; 292: 24-5
39. Kremer Hovinga TK, de Jong PE, Piers DA, et al. Diagnostic use of angiotensin converting enzyme inhibitors in radioisotope evaluation of unilateral renal artery stenosis. J Nucl Med 1989; 30: 605-14
40. Fommei E, Ghione S, Palla L, et al. Renal scintigraphic captopril test in the diagnosis of renovascular hypertension. Hypertension 1987; 10: 212-20
41. Visscher CA, de Zeeuw D, Huisman RM. Effect of chronic ACE-inhibition on the diagnostic value of renography for renovascular hypertension; a preliminary report. Nephrol Dial Transplant 1995; 10: 263-5
42. Buter H, Hemmelder MH, de Zeeuw D, et al. Hydrochlorothiazide potentiates the antiproteinuric efficacy of ACE-inhibition in patients with non-diabetic renal disease. In press
43. Gansevoort RT, de Zeeuw D, de Jong PE. Additive antiproleinuric effect of ACE inhibition and a low-protein diet in human renal disease. Nephrol Dial Transplant 1995; 10: 497-504
44. Apperloo AJ, de Zeeuw D, Sluiter HE, et al. Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease. BMJ 1991; 303: 821-4
45. Gansevoort RT, Sluiter WJ, Hemmelder MH, et al. The antiproteinuric effect of blood pressure lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10: 1963-74
46. Gansevoort RT, Heeg JE, Dikkeschei FD, et al. Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria. Nephrol Dial Transplant 1994; 9: 244-50
47. Rabelink AJ, Hené R, Erkelens DW, et al. Partial remission of nephrotic syndrome in patients on long-term simvastatin. Lancet 1990; 335: 1045-6
48. Keane WF, Kasiske BL, O'Donnell MP. Hyperlipidemia and the progression of chronic renal disease. Am J Clin Nutr 1988; 47: 157-60
49. Apperloo AJ, Zeeuw D de, de Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long term GFR decline in patients with non-diabetic renal disease. Kidney Int 1994; 45 Suppl.: 174S-178S
50. Gansevoort RT, de Zeeuw D, de Jong PE. Long-term benefits of the anti-proteinuric effect of ACE-inhibition in non-diabetic renal disease. Am J Kidney Dis 1993; 2: 202-6
51. Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990; 38: 384-94
52. de Jong PE, Anderson S, de Zeeuw D. Glomerular preload and afterload reduction as a tool to lower urinary protein leakage: will such treatments also help to improve renal function outcome? J Am Soc Nephrol 1993; 3: 1333-41
53. de Jong PE, Heeg JE, Apperloo AJ, et al. The antiproteinuric effect of blood-pressure lowering agents: differences between diabetics and non-diabetics. J Cardiovasc Pharmacol 1992; 19: Suppl. 6: 28S-32S
54. Apperloo AJ, de Zeeuw D, de Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate reflects long-term renal progression. Kidney Int 1994; 45; 174-8
55. Heeg JE, de Jong PE, Vriesendorp R, et al. Additive antiproteinuric effect of the NSAID indomethacin and the ACE inhibitor lisinopril. Am J Nephrol 1990; 10 Suppl. 1: 94-7
56. Mann JFE, Resich C, Ritz E. Use of angiotensin-converting enzyme inhibitors for the preservation of kidney function: it retrospective study. Nephron 1990; 55 Suppl.: 38-42
57. Kamper A-L, Strandgaard S, Leyssac PP. Late outcome of a controlled trial of enalapril treatment in progressive chronic renal failure: hard end-points and influence of proteinuria. Nephrol Dial Transplant 1995; 10: 1182-88
58. Hannedouche T, Landais P, Goldfarb B, et al. Randomised controlled trial of enalapril and beta-blockers in non-diabetic chronic renal failure. BMJ 1994; 309: 833-7
59. Zucchelli P, Zuccala A, Gaggi R. Comparison of the effects of ACE-inhibitors and calcium channel blockers on the progression of renal failure. Nephrol Dial Transplant 1995; 10 Suppl. 9: 46-51
60. van Essen GG, Rensma PL, de Zeeuw D, et al. Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 1996; 347: 94-5
61. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-4
62. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin-1 converting enzyme gene accounting for half of the variance in serum enzyme levels. J Clin Invest 1990; 86: 1343-6
63. Yoshida H, Mitarai T, Kawamura T, et al. Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995; 96: 2162-9
64. van der Kleij FHG, Navis GJ, Scheffer H, et al. ACE genotype does not determine short-term renal response to ACE inhibition in proteinuric patients. Nephrol Dial Transplant. In press
65. Chapman AB, Gabow PA, Schrier RW. Reversible renal failure associated with angiotensin-converting enzyme inhibitors in polycystic kidney disease. Ann Intern Med 1991; 115: 769-73
66. Toto RD, Mitchell HC, Lee H-C, et al. Reversible renal failure due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med 1991; 115: 513-9
67. Nath KA, Crumbles AJ, Murray BM, et al. Captopril and renal insufficiency. N Engl J Med 1983; 309: 666
68. Hené RJ, Boer P, Koomans HA, et al. Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1092; 21: 98-101
69. Textor SC, Bravo EL, Fouad FM. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med 1982; 73: 719-25
70. Ravid M, Savin H, Jutrin Y, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577-81
71. Björck S, Nyberg G, Mulec H, et al. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. BMJ 1986; 293: 467-70
72. Björck S, Mulec H, Johnsen SA, et al. Renal protective effects of enalapril in diabetic nephropathy. BMJ 1992; 304: 339-43
73. Ravid M, Neumann L, Lishner M. Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effects of ACE-inhibitors. Kidney Int 1995; 47: 907-10
74. Mulec H, Johnson SA, Wiklund O, et al. Cholesterol as a renal risk factor in diabetic nephropathy. Am J Kidney Dis 1993; 22: 193-201
75. Parving HH, Andersen AR, Smidt UM, et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ 1987; 294: 1443-7
76. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin convening enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62
77. Kasiske B, Kalil RSN, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129-38
78. Anderson S, Rennke HG, Garcia DL, et al. Short and long term effects of antihypertensive therapy in the rat. Kidney Int 1989; 36: 526-36
79. Viberti GC, Mogensen CE, Groop LC, et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994; 271: 275-9
80. Mathiesen ER, Hommel E, Giese J, et al. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991; 303: 81-7
81. Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up. Arch Intern Med 1996; 156: 286-9
82. Lebovitz HE, Wiegmann TB, Cnaan A, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int 1994; 45 Suppl. 45: 150S-55S
83. Mogensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346: 1080-4.
84. Tuck ML, Mayes DM. Mineralocorticoid biosynthesis in patients with hyporeninemic hypoaldosteronism. J Clin Endocrinol Metab 1980; 50: 341-7
85. Schambelan M, Sebastian A, Biglieri EG. Prevalence, pathogenesis and functional significance of aldosterone deficiency in hyperkalemic patients with chronic renal insufficiency. Kidney Int 1980: 17; 89-101
86. Toto RD. Renal insuffiency due to angiotensin-converting enzyme inhibitors. Miner Electrolyte Metab 1994; 20: 193-200
87. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-7
88. Kubo S, Nishioka A, Nishimura H, et al. Effects of captopril on arterial and venous pressure, renal function, and humoral factors in severe chronic congestive heart failure. Clin Pharmacol Ther 1984; 36: 456-63
89. Gavras I, Gavras H. Captopril and enalapril. Ann Intern Med 1983; 94: 58-9
90. Packer M, Lee WH, Medina N, et al. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 1987; 106: 346-54
91. Dzau VJ, Hollenberg NK. Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. Ann Intern Med 1984; 100: 777-82
92. Hoorntje SJ, Kallenberg CGM, Weening JJ, et al. Immunecomplex glomerulopathy in patients treated with captopril. Lancet 1980; 1: 1212-4
93. Smith WR, Neill J, Cushman WC, et al. Captopril-associated acute interstitial nephritis. Am J Nephrol 1989; 9: 230-5
94. Murphy BF, Whitworth JA, Kincaid-Smith P. Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics. BMJ 1984; 288: 844-5
95. DiBianco R. Adverse reactions with angiotensin converting enzyme (ACE) inhibitors. Medical Toxicol 1986; 1: 122-41
96. Shionoiri H. Pharmacokinetic drug interactions with ACE-inhibitors. Clin Pharmacokinet 1993; 25: 20-58
97. Murray MD, Brater DC. Renal toxicity of the non-steroidal anti-inflammatory drugs. Annu Rev Toxicol 1993; 435-65
98. Covi G, Minuz P, Capuzzo G, et al. Reduction in the antihypertensive effect of captopril induced by prostaglandin synthetase inhibition. Int J Clin Pharmacol Res 1984; 4: 47-52
99. Dzau VJ, Packer M, Lilly LS, et al. Prostaglandins in severe heart failure. N Engl J Med 1984; 310: 347-52
100. Heerdink ER, Leufkens HG, Herings RM, et al. NSAIDS increase the risk of congestive heart failure in elderly patients on diuretics. In press
101. Leonetti G, Cuspidi C, Choosing the right ACE inhibitor: a guide to selection. Drugs 1995; 49: 516-35
102. Carter BL. Dosing of antihypertensive medications in patients with renal insufficiency. J Clin Pharmacol 1995; 35: 81-6
103. Demeillers B, Jover B, Mimran A. Renal function in one kidney. one clip sodium-restricted rats: influence of enalapril and losartan. J Hypertens 1995; 13: 1764-6
104. Kohara K, Mikami H, Okuda N, et al. Angiotensin blockade and the progression of renal damage in the spontaneously hypertensive rats. Hypertension 1993; 21: 975-9
105. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological considerations. Am J Physiol 1993; 265: F477-86
106. Hutchinson FN, Webster SK. Effect of Ang II receptor antagonist on albuminuria and renal function in passive Heymann nephritis. Am J Physiol 1992; 263: F311-F318
107. Tanaka R, Kon V, Yoshioka T, et al. Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int 1994; 43: 537-42
108. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE-inhibition mediated by interference with the renin-angiotensin system? Kidney Int 1994; 45: 861-7
109. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403-7
110. 2 receptor mediates inhibition of cell proliferation in coronary endothelial cells. J CIm Invest 1995; 95: 651-7